Newron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia Transcript

Newron Pharmaceuticals discussed an FDA clinical hold and safety concerns involving its ENIGMA-TRS program for treatment-resistant schizophrenia. The provided text contains no details on the hold’s scope, duration, or financial impact.